Who is the CEO of Influx Healthtech Ltd?
- Answer Field
-
The CEO of Influx Healthtech Ltd is Dr. Munir Abdul Ganee Chandniwala.
BAJAJ BROKING
Influx Healthtech Limited, incorporated in September 2020, operates as a healthcare-focused Contract Development and Manufacturing Organization (CDMO). The company supports businesses in the nutraceutical, cosmetic, pharmaceutical, and wellness sectors by providing a complete range of services—from product development to regulatory guidance. Based in Mumbai, the company offers manufacturing solutions across multiple dosage forms, such as tablets, capsules, powders, softgels, gummies, jellies, effervescent tablets, oral films, and injectables. It also produces skincare, haircare, beard care, face masks, soaps, Ayurvedic and herbal products, veterinary feed supplements, and homecare goods.
The company manages three manufacturing units located in Thane, Maharashtra, with facility sizes of 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft. These facilities operate under globally recognised standards including GMP, HACCP, ISO 22000, and Halal certifications. As of June 11, 2025, Influx Healthtech employs 163 permanent staff, contributing to its operational and technical capabilities in contract manufacturing.
For more details, visit the Influx Healthtech IPO page.
Details | Information |
IPO Date | June 18, 2025 to June 20, 2025 |
Issue Size | 61,00,800 shares (aggregating up to ₹58.57 Cr) |
Price Band | ₹91 to ₹96 per share |
Lot Size | 1200 shares |
Listing At | NSE SME |
Purpose of the IPO
Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division
Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division
Purchase of Machineries for Homecare and Cosmetic Division
General Corporate Expenses
Event | Date |
---|---|
IPO Open Date | Wed, Jun 18, 2025 |
IPO Close Date | Fri, Jun 20, 2025 |
Tentative Allotment | Mon, Jun 23, 2025 |
Initiation of Refunds | Tue, Jun 24, 2025 |
Credit of Shares to Demat | Tue, Jun 24, 2025 |
Tentative Listing Date | Wed, Jun 25, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on June 20, 2025 |
Price Band for the IPO
₹91 to ₹96 per share
Minimum Lot Size and Application Details
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 1200 | ₹1,15,200 |
Retail (Max) | 1 | 1200 | ₹1,15,200 |
HNI (Min) | 2 | 2,400 | ₹2,30,400 |
Online Application Process
Log in to Your Trading Account
Access your trading account through your broker’s platform.
Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Select Influx Healthtech IPO
Find "Influx Healthtech IPO" and click on the ‘Apply’ button.
Enter Application Details
Specify the number of lots (minimum lot size: 1200 shares) and the bid price within the range of ₹91 to ₹96 per share.
Provide Your UPI ID
Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit
Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on June 20, 2025, to complete your application process.
Key Financial Metrics
Total Assets: Grew from ₹28.30 crore in FY23 to ₹70.30 crore as of March 2025.
Revenue: Reached ₹104.99 crore in FY25.
Profit After Tax (PAT): Stood at ₹13.37 crore for March 2025.
Net Worth: Recorded at ₹36.15 crore in FY25.
Reserves and Surplus: Recorded at ₹18.00 crore (March 2025), growing steadily over the years.
Total Borrowings: Stood at ₹0.22 crore in March 2025.
Recent Performance and Growth Prospects
The company has shown a consistent rise in its total assets over recent financial years, indicating expansion in operations and investments.
Revenue has progressed steadily, reflecting increased demand for the company’s manufacturing and development services.
Profit levels have improved, suggesting effective cost management and enhanced operational efficiency.
The company’s net worth has grown over time, highlighting financial stability and retained value generation.
Reserves and surplus have seen a positive trend, pointing to strengthened internal financial support and reinvestment capacity.
The borrowing levels remain minimal, suggesting reliance on internal accruals and controlled financial leverage.
These indicators collectively suggest a company with growing operational capacity and an improving financial position, with potential to support further expansion in the healthcare manufacturing sector.
Potential Risks of Investing in the IPO
The company operates in a highly regulated industry, where changes in compliance norms, licensing requirements, or safety standards could affect its operations and costs.
Dependence on a specific segment such as nutraceuticals or cosmetics may expose the business to sector-specific slowdowns or demand fluctuations.
Opportunities and Growth Potential
Expansion into new manufacturing divisions—nutraceuticals, veterinary food, homecare, and cosmetics—indicates a forward-looking strategy aimed at broadening its client base and operational capacity.
The company’s integrated model, from product development to regulatory support, allows it to serve a range of industries and adapt its offerings as market needs evolve.
KPI | Values |
ROE | 36.98% |
ROCE | 49.17% |
Debt/Equity | 0.01 |
RoNW | 36.98% |
PAT Margin | 12.75 |
Price to Book Value | 7.62 |
Registrar | Lead Manager(s) |
---|---|
Maashitla Securities Private Limited | Rarever Financial Advisors Pvt. Ltd. Pvt. Ltd. |
Influx Healthtech Limited
109, Ghanshyam Enclave Premises Co-op
Soc Plot No. 856, Laljipada
Kandivali West,
Mumbai, Maharashtra, 400067
Phone: +91 7045997809
Email: cs@influxhealthtech.com
Influx Healthtech Limited operates across multiple sectors within the healthcare and wellness manufacturing space. With its base in Mumbai and manufacturing units in Thane, the company offers a range of services covering product development, regulatory support, and contract manufacturing for various dosage forms and personal care segments.
The upcoming IPO is structured to support capital expenditure and operational expansion across different divisions. Interested participants may review the IPO details, objectives, and timelines to understand the offering in its current context.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Influx Healthtech IPO.
Share this article:
No result found
The CEO of Influx Healthtech Ltd is Dr. Munir Abdul Ganee Chandniwala.
The Influx Healthtech IPO is scheduled to open for subscription from June 18, 2025, and will close on June 20, 2025.
?
Influx Healthtech Ltd is a healthcare-focused Contract Development and Manufacturing Organization (CDMO). It provides manufacturing and development support to clients in the nutraceutical, cosmetic, pharmaceutical, and wellness sectors. The company’s business model includes diversified offerings, multiple product lines, and end-to-end services, which contribute to its operational continuity.
The issue size of the IPO is 61,00,800 equity shares, aggregating up to ₹58.57 crore.
‘Pre-apply’ refers to the facility where investors can submit their IPO application before the official opening date. The bid is processed once the IPO opens for public subscription.
An IPO order is considered placed once you successfully submit your application and approve the UPI mandate before the cut-off time, which is 5 PM on June 20, 2025.
The minimum order is 1 lot, comprising 1,200 shares. Retail investors can apply for a maximum of 1 lot.
The tentative allotment date is June 23, 2025.
The registrar of the IPO is Maashitla Securities Private Limited.
As of now, no publicly reported governance issues or board-related red flags have been identified in the available disclosures about Influx Healthtech Ltd.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading